At a biochemical level, the brains of patients with tauopathies harbor a spectrum of tau species ranging from low molecular weight fragments of degraded tau, through monomeric forms to soluble and insoluble high molecular weight species (Hyman, 2023; Tarutani and Hasegawa, 2022; Tarutani et al., 2022). Here, MAPT is linked to tauopathy.